Neuropsychological Evaluation for Early Diagnosis of PSP

Brief Title

Neuropsychological Evaluation for Early Diagnosis of PSP

Official Title

The Role of the Neuropsychological Evaluation for Early Diagnosis of Progressive Supranuclear Palsy

Brief Summary

      The aim of this study is to better understand the nature of the cognitive decline in
      Progressive Supranuclear Palsy, the time of its development and the relation with the other
      cardinal features of the disease.
    

Detailed Description

      Progressive Supranuclear Palsy (PSP) is a neurodegenerative disease characterized by vertical
      supranuclear gaze palsy, early balance dysfunction and falls. Tau-protein aggregation, mainly
      in the brainstem, is the disease hallmark. Because of the similarities with Parkinson's
      disease (PD), the diagnosis is made approximately 4 years after the symptoms onset. Cognitive
      deficits are a leading feature of PSP and they actually represent one of the four functional
      core domains in the revised diagnostic criteria. The aim of this study is to better
      understand the nature of this cognitive decline, the time of its development and the relation
      with the other cardinal features of the disease.
    

Study Type

Observational

Primary Outcome

MMSE

Secondary Outcome

 6MWT

Condition

Progressive Supranuclear Palsy

Intervention

Cognitive evaluation

Study Arms / Comparison Groups

 PSP patients

Description:  Patients suffering from Progressive Supranuclear Palsy (PSP)

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Status

Behavioral

Estimated Enrollment

112

Start Date

January 1, 2016

Completion Date

March 2, 2018

Primary Completion Date

March 1, 2018

Eligibility Criteria

        Inclusion Criteria:

          -  Patients fulfilling the criteria for idiopathic PD

          -  Patients fulfilling the criteria for PSP

        Exclusion Criteria:

          -  Any other neurodegenerative disorders or medical conditions different from PD / PSP
      

Gender

All

Ages

N/A - N/A

Contacts

Giuseppe Frazzitta, MD, , 

NCT ID

NCT03478124

Organization ID

NPsy-PSP

Responsible Party

Sponsor

Study Sponsor

Ospedale Generale Di Zona Moriggia-Pelascini

Study Sponsor

Giuseppe Frazzitta, MD, Principal Investigator, Department of Parkinson's disease, Movement Disorders and Brain Injury Rehabilitation, "Moriggia-Pelascini" Hospital - Via Pelascini, 3, 22015, Gravedona ed Uniti, Como, Italy

Verification Date

March 2018